Document:

<PAGE>

                                                                    EXHIBIT 10.4

                           RESEARCH FUNDING AGREEMENT

               THIS RESEARCH FUNDING AGREEMENT (the "AGREEMENT") is made as of
this ___ day of August, 2000, by and between AVAX TECHNOLOGIES, INC., a Delaware
corporation ("AVAX") and GENOPOIETIC, S.A., a French SOCIETE ANONYME
("GENOPOIETIC"). Capitalized terms used herein and not otherwise defined herein
shall have the meanings attributed to them in the Stock Contribution Agreement
(as defined below).

               WHEREAS, AVAX and Genopoietic, among others, have entered into
that certain Stock Contribution Agreement as of the 17th day of July, 2000 (the
"STOCK CONTRIBUTION AGREEMENT") in accordance with the terms of which AVAX now
desires to contribute certain amounts of money to Genopoietic in order to fund
the ongoing and future scientific research activities of Genopoietic and
Genopoietic desires to perform such research activities.

               NOW, THEREFORE, in consideration of the mutual covenants and
agreements set forth herein and in the Stock Contribution Agreement, and for
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, AVAX and Genopoietic hereby agree as follows:

         SECTION 1. RESEARCH FUNDS. Subject to the fulfillment of the Funding
Conditions (as defined below), AVAX agrees to provide funding to Genopoietic
from time to time for the direct costs of basic scientific research in areas of
mutual interest to AVAX and Genopoietic in an aggregate amount of up to Eight
Million United States Dollars (US$ 8,000,000) (the "RESEARCH FUNDS") payable
over the initial period from the date hereof through July 31, 2001 (the "INITIAL
PERIOD") and the four (4) twelve month periods thereafter (each, a "FUNDING
YEAR") ending on July 31, 2005 (the "FUNDING TERM"). The Research Funds shall be
provided as additional contributions to the capital of Genopoietic or as payment
of indebtedness owed by Genopoietic to third parties or as a long-term loan to
Genopoietic, at AVAX's option.

         SECTION 2. INITIAL PAYMENT. Contemporaneously with the execution of
this Agreement, as a part of the Research Funds, AVAX shall transfer to
Genopoietic an initial amount of approximately Two Hundred Thirty-Six Thousand
United States Dollars (US $236,000) (the "INITIAL PAYMENT") to pay for the
following:

               (a)  the amount to be paid by Genopoietic on the date hereof to
         L'UNIVERSITE PIERRE ET MARIE CURIE ("UPMC") pursuant to that certain
         CONVENTION dated as of the 19th day of July, 2000 (the "UPMC
         AGREEMENT") to purchase certain intellectual property rights; plus

               (b)  the amount to be paid by Genopoietic to UPMC pursuant to the
         UPMC Agreement in exchange for the forgiveness of certain indebtedness
         owed to UPMC by Genopoietic.

Genopoietic shall use the Initial Payment and the Research Funds to pay the
debts of Genopoietic as they come due.

         SECTION 3. FORMATION OF RESEARCH COMMITTEE; ANNUAL RESEARCH BUDGET.

         (a)   AVAX and Genopoietic shall form a research committee (the
"COMMITTEE") comprised of four (4) members, two (2) members appointed by AVAX,
one (1) member appointed by Professor David

                                        1

<PAGE>

R. Klatzmann ("PROF. KLATZMANN") and one (1) member appointed by Professor
Jean-Loup Salzmann ("PROF. SALZMANN"). The Committee shall meet (i) as soon as
practicable after the date of this Agreement to develop a research funding
budget for Genopoietic for the Initial Period and the Funding Year immediately
thereafter (the "INITIAL BUDGET") and (ii) prior to the beginning of each
Funding Year thereafter to develop a research funding budget for Genopoietic for
the following Funding Year (each, an "ANNUAL RESEARCH BUDGET"). The Initial
Budget shall be approved by a majority vote of the members of the Committee, and
upon approval by the Committee and in no event later than three (3) months after
the Closing, such Initial Budget shall be submitted to the Board of Directors of
AVAX (the "BOARD") for final approval, which approval may be withheld in the
Board's reasonable discretion. Thereafter, each Annual Research Budget shall be
approved by a majority vote of the members of the Committee. Upon approval of
each such Annual Research Budget by the Committee and in no event later than
three (3) months prior to the commencement of the Funding Year to which such
Annual Research Budget relates, the Committee shall submit such approved Annual
Research Budget to the Board for final approval, which approval may be withheld
in the Board's reasonable discretion. If the Committee is unable to reach
majority agreement on the Initial Budget or any Annual Research Budget or if the
Initial Budget or any Annual Research Budget is approved by the Committee but
not approved by the Board, then the Board shall determine the Initial Budget or
Annual Research Budget, as appropriate, for the applicable period based on the
overall interests of AVAX taken as a whole (an "AVAX BUDGET"). (The Initial
Budget, each Annual Research Budget and any AVAX Budget shall be generally
referred to herein as a "BUDGET.")

         (b)   Each Budget shall provide a detailed description of all research
milestones to be achieved during the period to which such Budget relates,
including, but not limited to the activities listed in Section 4(a)(iii)-(vii)
(the "RESEARCH MILESTONES"). Each Budget shall also set forth the amount of
Research Funds to be paid by AVAX to Genopoietic pursuant to such Budget and
shall provide a schedule for the payment of all such Research Funds; provided,
however, that, subject to Section 5 below, the aggregate amount to be funded by
AVAX to Genopoietic in any Funding Year shall not be reduced below Eight Hundred
Thousand United States Dollars (US $800,000).

         (c)   After the Board either approves the Initial Budget or creates an
AVAX Budget for the Initial Period and the Funding Year thereafter, the
Committee shall meet at least once each calendar quarter during the Funding Term
to review the current Budget and make any changes that it deems appropriate
(each, an "AMENDED BUDGET"). Each Amended Budget shall be approved by a majority
vote of the members of the Committee. If the Committee is unable to reach
majority agreement on any Amended Budget, the Board shall determine the Amended
Budget. If an Amended Budget is approved by the Committee or the Board, such
Amended Budget shall replace the then-current Budget in its entirety, and such
Budget shall be of no further force or effect.

         SECTION 4. FUNDING CONDITIONS.

         (a)   AVAX's obligations to provide Research Funds to Genopoietic is
conditioned on the fulfillment of all of the following conditions as of the date
of each funding (the "FUNDING CONDITIONS"):

               (i)  Prof. Klatzmann, Prof. Salzmann and Genopoietic shall each
         be in full compliance with all of the covenants and agreements
         contained in this Agreement, and this Agreement shall remain in full
         force and effect in accordance with its terms;

               (ii) Prof. Klatzmann and Prof. Salzmann shall each be in full
         compliance with all of their duties and obligations pursuant to the
         Stock Contribution Agreement and all other agreements or documents
         executed by both or either of them pursuant to such Stock Contribution

                                        2

<PAGE>

         Agreement and all such documents shall remain in full force and effect
         in accordance with their terms;

               (iii) Prof. Klatzmann shall use his best efforts to make no less
         than three (3) oral presentations primarily relating to the research
         funded by AVAX during the Initial Period and each Funding Year at
         scientific conferences or meetings ("Presentations"); provided,
         however, that Prof. Klatzmann shall not knowingly or voluntarily
         participate in any way in any Presentation without the prior written
         approval of AVAX, which approval will not be unreasonably withheld.
         AVAX agrees to respond to the request for Presentation within fifteen
         (15) days after receipt of such request; provided, however, that such
         fifteen (15) day time period may be extended if AVAX determines the
         contents of such Presentation should be reviewed by intellectual
         property counsel or similar advisors. During each Presentation given
         during the Funding Term, Prof. Klatzmann shall acknowledge, in a light
         and manner favorable to AVAX, that AVAX has provided substantial
         funding and support for the research activities;

               (iv) Prof. Klatzmann shall use his best efforts to have no less
         than two (2) manuscripts primarily relating to the research funded by
         AVAX submitted or accepted for publication in peer-reviewed journals
         ("Publications") during the first two years of the Funding Term (I.E.
         during the Initial Period and the Funding Year thereafter) and during
         each Funding Year thereafter shall have no less than two (2)
         manuscripts accepted for publication in peer-reviewed journals;
         provided, however, that Prof. Klatzmann shall not knowingly or
         voluntarily participate in any way in any Publication without the prior
         written approval of AVAX, which approval will not be unreasonably
         withheld. AVAX agrees to respond to the request for Publication within
         thirty (30) days after receipt of such request; provided, however, that
         such thirty (30) day time period may be extended if AVAX determines the
         contents of such Publication should be reviewed by intellectual
         property counsel or similar advisors. In each Publication published
         during the Funding Term, Prof. Klatzmann shall acknowledge, in a light
         and manner favorable to AVAX, that AVAX has provided substantial
         funding and support for the research activities;

               (v)  In the event that Prof. Klatzmann is involved in any
         collaboration (either written or oral) that does not involve the
         research funded by AVAX (as described in Section 3 above), Prof.
         Klatzmann shall provide a "courtesy copy" to the Chief Executive
         Officer of AVAX of any presentation and/or publication material or
         information resulting from such collaboration as soon as reasonably
         practicable prior to public disclosure of such material or information;

               (vi) During the period covered by the Initial Budget, Prof.
         Klatzmann and Prof. Salzmann shall conduct research in the following
         areas, among others: vectorization, TK Gene on cancer prevention and
         GVHD, chrondrocytes and tenocytes and improvements on the AVAX vaccine
         technology; provided, however, that these targets may change upon the
         mutual written consent of parties hereto;

               (vii) Within twelve (12) months after the Closing Date, Prof.
         Klatzmann and Prof. Salzmann shall treat patients with haptenized
         autologous vaccine in at least one (1) clinical trial based in France
         and work on second generation applications or combinations with such
         vaccine;

               (viii) the Consulting Period (as defined in each of Prof.
         Klatzmann's and Prof. Salzmann's Consulting and Assignment Agreements)
         shall remain in full force and effect in accordance with the terms of
         such agreements; and

                                        3

<PAGE>

               (ix) Genopoietic shall have achieved all Research Milestones
         contained in each Budget or Amended Budget during the period covered by
         such Budget or Amended Budget, as the case may be.

         (b)   If Genopoietic does not meet any of the above Funding Conditions
at any time during the Funding Term, AVAX may, in AVAX's sole discretion,
immediately terminate this Agreement and all of AVAX's duties and obligations
hereunder.

         SECTION 5. LIMITATION ON FUNDING OBLIGATION. AVAX agrees that it will
use commercially reasonable efforts to have sufficient funds to meet its funding
obligations hereunder. If, however, at any time AVAX determines that it is
unable to allocate sufficient funds to meet its obligations hereunder,
Genopoietic acknowledges and agrees that AVAX shall not be required to fund the
Research Funds until such time as AVAX determines it has sufficient funding to
resume its obligations hereunder and any such suspension of funding hereunder
shall not otherwise affect the terms of this Agreement.

         SECTION 6. MISCELLANEOUS.

         (a)   NOTICES. All notices, requests, claims, demands or other
communications required or permitted by this Agreement or any instrument
provided for herein to be given or made by the parties shall be in writing
(including, without limitation, by telecopy) and shall be deemed delivered if
delivered in person, by telecopy or by registered or certified mail (postage
prepaid, return receipt requested) to the respective parties:

         If to AVAX:         AVAX Technologies, Inc.
                             Attention: Dave Tousley
                             4520 Main Street, Suite 930
                             Kansas City, Missouri 64111 USA

         with a copy to:     Shook, Hardy & Bacon L.L.P.
                             Attention:  Kevin R. Sweeney, Esq.
                             1010 Grand Boulevard, Suite 500
                             Kansas City, Missouri 64106 USA

         If to Genopoietic:  Genopoietic, S.A.
                             22 rue Esquirol
                             75013 Paris, France

         Either of the respective parties may, however, designate in writing
such new or other addresses or telecopy numbers to which such notice shall
thereafter be mailed or telecopied. Any notice or demand given in accordance
with this section shall be deemed received on the date of receipt by the
recipient thereof if received prior to 5 p.m. in the place of receipt and such
day is a business day in the place of receipt. Otherwise, any such notice,
request or communication shall be deemed not to have been received until the
next succeeding business day in the place of receipt.

         (b)   SUCCESSORS AND ASSIGNS. The provisions of this Agreement shall
be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns. No party shall assign, delegate or otherwise
transfer any of its rights or obligations under this Agreement without the prior
written consent of each other party hereto. Notwithstanding the preceding
sentence, however, AVAX may assign all or any part of its rights, interests or
obligations hereunder to any of its parents, subsidiaries

                                        4

<PAGE>

or affiliates without the prior written consent of Genopoietic, provided that
such assignment shall not release AVAX from its obligations hereunder.

         (c)   GOVERNING LAW. This Agreement shall be governed by, and
construed and enforced in accordance with, the laws of the State of Missouri,
United States of America, without giving effect to the choice of law provisions
of such State.

         (d)   COUNTERPARTS. This Agreement may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if the
signature thereto and hereto were upon the same instrument. No provision of this
Agreement is intended to confer upon any person or entity other than the parties
hereto any rights or remedies hereunder.

         (e)   PUBLICITY. AVAX and Genopoietic each agree that press releases
and other announcements or disclosure with respect to the transactions
contemplated by this Agreement shall be subject to mutual agreement to the
maximum extent feasible consistent with the parties' respective legal
obligations.

         (f)   ENTIRE AGREEMENT. This Agreement, the Stock Contribution
Agreement and the Consulting Agreements, including any Schedules and Exhibits
attached hereto or thereto, which are all hereby expressly incorporated herein
by this reference, constitutes the entire agreement between the parties with
respect to the subject matter of this Agreement and supersedes all prior
agreements and understandings, both oral and written, between the parties with
respect to the subject matter of this Agreement. No representation, inducement,
promise, understanding, condition or warranty not set forth herein has been made
or relied upon by either party hereto.

         (g)   MODIFICATIONS, AMENDMENTS AND WAIVERS. At any time the parties
hereto may, by written agreement signed by the parties (i) extend the time for
the performance of any of the obligations or other acts of the parties hereto,
(ii) waive compliance with any of the covenants or agreements contained in this
Agreement or (c) otherwise amend this Agreement.

         (h)   HEADINGS. The section and paragraph headings contained in this
Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement.

         (i)   JURISDICTION. The parties acknowledge that this Agreement was
drafted, negotiated and executed in large part in Kansas City, Missouri, United
State of America. Except as otherwise expressly provided in this Agreement, any
suit, action or proceeding seeking to enforce any provision of, or based on any
matter arising out of or in connection with, this Agreement or the transactions
contemplated hereby shall be brought in the United States District Court for the
Western District of Missouri or in any Missouri State Court sitting in Kansas
City, Missouri, and each of the parties hereby consents to the jurisdiction of
such courts (and of the appropriate appellate courts therefrom) in any such
suit, action or proceeding and irrevocably waives, to the fullest extent
permitted by law, any objection which it may now or hereafter have to the laying
of the venue of any such suit, action or proceeding in any such court or that
any such suit, action or proceeding which is brought in any such court has been
brought in an inconvenient forum. Process in any such suit, action or proceeding
may be served on any party anywhere in the world, whether within or without the
jurisdiction of any such court. Without limiting the foregoing, each party
agrees that service of process on such party as provided in Section 6.1 shall be
deemed effective service of process on such party.

                                        5

<PAGE>

         (j)   WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY
IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY.

         (k)   INTERPRETATION. In the event any portion of this Agreement shall,
for any reason, be held to be invalid, illegal or unenforceable in whole or in
part, the remaining provisions shall not be affected thereby and shall continue
to be valid and enforceable. If, for any reason, a court finds that any
provision of this Agreement is invalid, illegal or unenforceable as written, but
by limiting such provision it would become valid, legal and enforceable, then
such provision shall be deemed to be written, construed and enforced as so
limited. Words and phrases herein shall be construed as in the singular or
plural number, and as masculine, feminine or neuter gender, according to the
context. Nothing contained in this Agreement and no action taken by the parties
pursuant hereto shall be deemed to constitute a partnership, an association, a
joint venture or other entity between the parties.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                        6

<PAGE>

               IN WITNESS WHEREOF, AVAX and Genopoietic have caused this
Agreement to be executed by their respective duly authorized legal
representatives as of the date first above written.

                             AVAX TECHNOLOGIES, INC., a Delaware
                             Corporation

                             By:
                                ---------------------------------------
                                Name:  Jeffrey M. Jonas, M.D.
                                Title: President and Chief Executive Officer

                             GENOPOIETIC, S.A., a French SOCIETE
                             ANONYME

                             By:
                                ---------------------------------------
                                Name:  Charles Salzmann
                                Title: President Directeur General

                                        7Prepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document
 

Exhibit (10)A 

  AGREEMENT         

    THIS AGREEMENT is made effective as of the 8th day of June, 2000 by and among TARGET CORPORATION, a Minnesota corporation ("Company") and LARRY V. GILPIN
("Executive"). 

RECITALS 

    A.  Executive
is employed by the Company; and 

    B.  The
Company and Executive wish to sever the Company's and Executive's relationship as employer and employee respectively, on the terms and conditions thereafter set
forth; and 

    C.  The
Company maintains an Income Continuance Policy (the "ICP") for which Executive is eligible, the terms and provisions of which Executive has been subject to and
is familiar with; and 

    D.  The
Company delivered Notice of Termination to Executive on May 15, 2000. 

    E.  The
ICP requires a release in writing from Executive; and 

    F.  Executive
acknowledges he has been advised and encouraged to review this Agreement with an attorney and is fully aware of the potential rights and remedies he may
have as a result of the severance; and 

    G.  Executive
and the Company wish to memorialize herein the resolution and settlement of all their respective rights, remedies and obligations whatsoever, flowing from
Executive's employment and relationship with the Company and the severance and termination of that employment and relationship. 

    H.  Capitalized
terms used, but not defined, in this Agreement shall have the definitions ascribed to them in the ICP. 

     1.  Employment Severance Date.  Executive's Effective Date
of Termination for ICP purposes is June 3, 2000. Executive shall perform duties assigned to him by the Company through June 3, 2000, when the employer-employee relationship of Executive
and the Company shall be severed and terminated (the "Employment Severance Date"). Executive's final day on the premises of the Company shall be May 19, 2000. After the Employment Severance
Date, Executive shall be considered to be retired from his employment with the Company. As a retired officer of the Company, he shall be entitled to all benefits normally afforded to other retired
executives as currently exist or as otherwise modified in the future. 

     2.  Salary.  Executive shall be paid his regular salary for
services rendered as an employee under paragraph 1 hereof through June 3, 2000, subject to all required and voluntary withholdings. Such payments will otherwise be made in accordance
with the Company's standard payroll practices as in effect at the time of payment. 

     3.  Income Continuance Payments.  Executive shall be
entitled to income continuance payments aggregating $2,500,512, which shall be paid in fifty-two (52) consecutive biweekly payments pursuant to and subject to the terms and
conditions of the ICP, the first payment commencing on the first regular payroll date after the later of (i) the expiration of the revocation period described in Section 23 of this
Agreement or (ii) June 2, 2000. The gross amount of each biweekly payment, subject to the terms and conditions of the ICP, shall be $48,086.77. The biweekly amounts shall be reduced for
taxes and other amounts required to be withheld by the Company. 

     4.  Vacation Pay.  The Company shall pay to Executive any
unused accrued vacation due Executive as of the Employment Severance Date, subject to all required withholdings. 

     5.  Health Insurance.  Executive may continue to participate
in the Company's medical and dental programs to the extent, if any, permitted by the Company's medical and dental plans (the "Plans"). In 

order to continue such coverage, Executive must maintain continuous coverage under the Plans and pay 102% of the full cost of such Plans. Executive acknowledges that the Company may modify its premium
structure, the terms of the Plans and the coverages of the Plans, including the termination of all or part of any Plan. All insurance coverage shall terminate at the earlier of 18 months from
the Employment Severance Date or when the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"), permits terminations. 

     6.  Life Insurance.  Executive may take his universal life
insurance policy, if any, with him after the Employment Severance Date. In order to continue such policy, he will be required to make all payments with respect to the policy. 

     7.  Pension Plan - Savings Plan.  Executive's rights, if
any, under the Company's Pension Plan and the Target Corporation 401(k) Plan will be determined under the terms of such plans as amended from time to time. 

     8.  Deferred Compensation Plan.  Executive shall be paid his
deferred benefits, if any, under the Target Corporation Deferred Compensation Plan Senior Management Group and the Target Corporation SMG Executive Deferred Compensation Plan pursuant to the terms of
such plans as amended from time to time. 

     9.  Excess Pension Plan.  Executive will be paid his
benefits, if any, under the Target Corporation Excess Pension Plan pursuant to the terms of such plan as amended from time to time. 

    10.  Stock Plan.  Executive's rights under the Dayton Hudson Corporation
Executive Long Term Incentive Plans of 1981 and 1999 (collectively, the "LTIP") will be determined under the terms of such plans on the Employment Severance Date. Executive acknowledges that the
extension of option exercise periods under Section 6.1(b)(iii) of the LTIP, requires the consent of the Compensation Committee of the Board of Directors. Executive further acknowledges
that such consent is in the sole discretion of such Committee. The Company will recommend that the Compensation Committee extend Executive's outstanding stock options such that they shall continue to
vest and may be exercised for a period of five years from the Employment Severance Date or ten years and one day after the date of grant of the option, whichever occurs first; provided, however, that
such extension will be contingent upon Executive's compliance with the terms of this Agreement and Executive's stock options may be terminated earlier as provided in paragraph 17 of this
Agreement. 

    11.  Other Benefits.  

    On
or before the Employment Severance Date, Executive may purchase his company car for a price equal to the value of such car as carried on Target Stores' books at the time of such
purchase. 

    The
Company shall reimburse the Executive for financial counseling expenses incurred as of June 3, 2000 under the Financial Counseling Expense Reimbursement perquisite for
financial counseling expenses incurred prior to the Employment Severance Date. Eligibility of expenses shall be determined in accordance with the Company's standard policy for reimbursement of such
expenses to its officer group. 

    Except
as set forth in this Agreement or as required by law, Executive is entitled to no other employee benefits, fringe benefits or compensation, including, without limitation, any
payment from the Company pursuant to its Short-Term Incentive Plan for fiscal year 2000 performance. 

    12.  No Recruiting.  Executive agrees, unless he has a written agreement
signed by the an authorized officer of the Company allowing Executive to recruit persons named in that agreement, the execution of which agreement shall be in the sole discretion of the such officer,
that Executive will not recruit for employment, directly or indirectly, any employee of the Company or any subsidiary of the Company, until the later of the dates upon which Executive has the right to
(i) receive payments pursuant to paragraph 3 of this Agreement, or (ii) exercise stock options under the LTIP. 

    13.  Consultation and Cooperation.  Following the Employment Severance Date,
the Company may request that Executive consult or cooperate with the Company (including, without limitation, serving as a 

witness or testifying on the Company's behalf without subpoena), and Executive agrees to be available at mutually agreeable times to perform such duties and provide such cooperation in connection with
various business and legal matters in which Executive was involved or has knowledge as result of Executive's employment with the Company. In so consulting or cooperating, Executive shall be reimbursed
his reasonable out-of-pocket expenses and he shall not be nor represent to anyone that he is an agent of the Company, unless expressly authorized in writing to do so by an
authorized officer of the Company. 

    14.  Directly Competitive Employment.  For purposes of Section II.G
of the ICP and paragraph 17 of this Agreement, "Directly Competitive Employment" shall be employment with Best Buy, Wal-Mart, Kohl's, or any entity that controls, is controlled by
or is under common control with any of these companies. For purposes of this paragraph 14, "control", "controls" or "controlled by" shall mean having a majority ownership interest or majority
voting interest in the other company. 

    15.  Confidentiality.  Executive understands and agrees that the existence
and terms of this Agreement are confidential and are not to be disclosed by Executive to anyone other than Executive's spouse, attorney, financial advisor, tax advisor (each of whom must agree to keep
it confidential) or pursuant to court order. 

    Executive
represents and warrants that prior to signing this Agreement he has not disclosed the terms of this Agreement or any information regarding the negotiations or discussions
regarding this Agreement to anyone other than his spouse, attorney, financial advisor or tax advisor (each of whom has agreed to keep such information confidential). 

    Executive
recognizes and acknowledges that confidential information of various kinds; including, but not limited to the Company's or any of its subsidiaries' (i) employee and
personnel data and information, (ii) present, past and future strategies, plans, and proposals (including, but not limited to, customer, merchandising, marketing and store operation
strategies), (iii) financial information, and (iv) present, past and future personnel and labor relations strategies, plans, practices, policies, training programs and goals, are
valuable, special and unique assets of the Company. Executive will not, during or after Executive's employment with the Company, disclose or use, or cause or permit to be disclosed or used, any such
information, to or by any person, firm, corporation, association or other entity for any reason or purpose other than for the sole benefit of the Company. 

    Executive
represents that he has not removed and will not remove any of the Company's property from the Company's premises. This includes, but is not limited to, business records,
manuals, customer lists and records, business forms, personnel lists, information, plans, training materials, and records, information regarding suppliers and vendors, marketing and strategy plans,
contracts, contract information, correspondence, computer tapes and diskettes, data processing and other computer reports, and business files. 

    16.  Detrimental Conduct.  Executive agrees that he will not directly or
indirectly in any manner by word or action defame or slander the Company, any subsidiary of the Company, or any of their management or affiliates, or state or utter an untruth or misstatement of fact
that affects any of its or their reputations. 

    17.  Termination of Benefits.  In addition to other remedies available to
the Company, in the event Executive breaches any of his obligations under this Agreement, then (i) the Company shall be relieved of all liability and obligation to make any payments under this
Agreement, (ii) all of Executive's stock options and rights to receive performance shares and restricted stock shall terminate immediately and (iii) the Company may demand the return of
any payments theretofore paid to Executive under paragraph 3. In addition, all of Executive's stock options and rights to receive performance shares and restricted stock shall terminate
immediately if Executive engages in "Directly Competitive Employment" as defined in paragraph 14 of this Agreement. Even if payments and benefits are terminated pursuant to this paragraph, 

Executive's obligations under paragraphs 12, 13, 14, 15 and 16 hereof, and the release set forth in paragraph 18 hereof shall remain in full force and effect. 

    18.  Release.  

    A.  DEFINITIONS.
All words used in this release are intended to have their plain meanings in ordinary English. Specific terms in this release have the following
meanings: 

    1)  "Executive"
includes Executive and anyone who has or obtains any legal rights or claims through Executive. 

    2)  "Company"
includes, as appropriate, any company related to the Company in the present or past, any entity providing insurance to the Company in the present or past,
any present or past employee benefit plan sponsored by the Company, the Company's present or past officers, directors, employees and agents and any person who acted on behalf of the Company or on
instructions from the Company. 

    3)  "Executive
Claims" means all of the rights Executive has now to any relief of any kind from the Company, whether or not Executive knows about the rights or claims,
including without limitation: 

    a.  All
claims Executive has now arising out of his employment with the Company and his employment termination and all claims that arise out of or that relate to
statements or actions of the Company; including, but not limited to, claims relating to breach of contract; unpaid compensation or benefits; breach of the covenant of good faith and fair dealing;
promissory or equitable estoppel; breach of fiduciary duty; violation of the Age Discrimination in Employment Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991,
Section 1981 of the Civil Rights Act of 1866, the Equal Pay Act of 1963, the Family and Medical Leave Act, the Americans with Disabilities Act, the Minnesota Human Rights Act and other federal,
state, and local civil rights or discrimination laws; violation of the Employee Retirement Income Security Act of 1974; violation of the National Labor Relations Act; harassment; retaliation or
reprisal; constructive discharge; invasion of privacy; violation of public policy; Executive's conduct as a "whistleblower"; fraud or misrepresentation; defamation; intentional or negligent infliction
of emotional distress; negligence; interference with contractual or business relationships; interference with prospective economic advantage; wrongful termination of employment; assault; battery;
unlawful employment practices, including all claims or causes of action in tort or contract;1 and any other conduct prohibited under any federal, state or local statute, ordinance or
regulation; and 

	1
	Any
references to government statutes include any amendments to such statutes. 

    b.  All
claims for attorneys' fees and costs and other litigation expenses. 

    B.  AGREEMENT
TO RELEASE EMPLOYEE CLAIMS. In consideration of the Company having entered into this Agreement, Executive agrees to give up all Executive Claims against
the Company as described above. Executive will not bring any lawsuits or make any other demands against the Company based on Executive Claims. The consideration represented by this Agreement exceeds
any earned wages or other amounts due and owing to Executive and represents full and fair consideration to Executive for the release of Executive Claims. The Company does not owe Executive anything in
addition to what Executive is specifically entitled to pursuant to the terms of this Agreement. 

    C.  ADDITIONAL
AGREEMENTS AND UNDERSTANDINGS. Even though the Company has agreed to the terms and conditions of this Agreement to obtain Executive's release of
Executive Claims, the Company does not admit that it may be responsible or legally obligated to Executive. In fact, the Company denies that it is responsible or legally obligated for Executive Claims
or that it has engaged in any wrongdoing. 

    19.  Miscellaneous.  This Agreement shall be binding upon the Company and
its successors and assigns and Executive, his heirs, executors, successors and assigns. This Agreement embodies the entire Agreement and understandings between the Company and Executive, and
supersedes all prior agreements and understandings (oral or written) between them relating to the subject matter hereof. The terms of this Agreement may only be modified by an agreement in writing
signed by Executive and an authorized officer of the Company. 

    20.  Construction and Applicable Law.  The ICP is intended to be a welfare
benefit plan subject to the applicable requirements of ERISA. The ICP and this Agreement shall be administered and construed consistently with that intent. They shall also be construed and
administered according to the laws of the State of Minnesota to the extent such laws are not preempted by laws of the United States of America. All controversies, disputes, and claims arising
hereunder shall be submitted to the United States District Court for the District of Minnesota. 

    21.  Severability.  Invalidation of any provision contained in this
Agreement, or of the application thereof to any party, by judgment or court order shall in no way affect any of the other provisions hereof or the application thereof to any other party or
circumstance and the same shall remain in full force and effect, unless enforcement of this Agreement as so invalidated would be unreasonable or grossly inequitable under all the circumstances or
would frustrate the purposes of this Agreement. 

    22.  Relationship to Income Continuance Plan.  This Agreement is entered
into for the purpose of implementing the ICP. The terms of this Agreement are intended to be construed in concert with the terms of the ICP. To the extent there is conflict between the terms of this
Agreement and the terms of the ICP, the terms of this Agreement shall prevail. 

    23.  Revocation.  Executive understands that he may revoke (that is cancel)
the release set forth in paragraph 18, if he does so within 15 calendar days of signing this Agreement. Such revocation must be made in a written statement that is hand delivered or post marked
within 15 calendar days of the date Executive signs this Agreement and must be addressed to the Corporate Secretary, Target Corporation, 777 Nicollet Mall, Minneapolis, Minnesota 55402. Executive
understands that if he mails such a revocation, mailing by certified mail, return receipt requested, is recommended to show proof of mailing. 

    24.  Remedies.  In the event of a breach or threatened breach by Executive
of the provisions of paragraphs 12, 13, 14, 15 or 16 of this Agreement, Company shall be entitled to an injunction restraining Executive from breaching, in whole or in part, any of his duties,
obligations, or covenants in those paragraphs. Executive acknowledges that such remedy is appropriate. Nothing in this Agreement shall be construed as prohibiting Company from pursuing any other
remedy or remedies available to it for such breach or threatened breach, including but not limited to the other remedies specifically provided for in this Agreement and the recovery of damages,
together with costs and attorney's fees. 

Please read carefully before signing 

	•
	Executive
acknowledges that he has been advised and encouraged to consult with an attorney prior to signing this Agreement.

	•
	In
agreeing to sign this Agreement, Executive acknowledges that he has not relied on any statements or explanations made by the Company or its attorneys.

	•
	Executive
acknowledges that he has been given 21 days (or more) to consider whether to sign this Agreement. Executive acknowledges that if he signs
this Agreement before the end of the 21 day period, it was Executive's personal, voluntary decision to do so.

	•
	Executive
understands that this Agreement shall not become effective or enforceable until the revocation period has expired. No payment shall be made to
Executive until after the revocation period has expired.

	•
	Executive
understands that if he revokes this Agreement it will terminate and he will not receive any benefits under this Agreement including, without
limitation, the payments set forth in paragraph 3 and the option extension described in paragraph 10. 

    IN
WITNESS WHEREOF the parties have hereto executed this Agreement. 

	 	 	TARGET CORPORATION
	 

Date: 6/8/00	 
 	 

By:	 
 	 

/s/            
	 	 	 	 	
 James T. Hale
	 	 	Title:	 	Executive Vice President

& General Counsel
	 

Date: 6/13/00	 
 	 

 	 
 	 

/s/                 
	 	 	 	 	
 LARRY V. GILPIN

QuickLinks

AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]